Rankings
▼
Calendar
VCEL
Vericel Corporation
$2B
Q1 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$51M
+25.0% YoY
Gross Profit
$35M
68.9% margin
Operating Income
-$5M
-10.7% margin
Net Income
-$4M
-7.5% margin
EPS (Diluted)
$-0.08
QoQ Revenue Growth
-21.1%
Cash Flow
Operating Cash Flow
$7M
Free Cash Flow
-$7M
Stock-Based Comp.
$10M
Balance Sheet
Total Assets
$357M
Total Liabilities
$123M
Stockholders' Equity
$234M
Cash & Equivalents
$71M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$51M
$41M
+25.0%
Gross Profit
$35M
$27M
+33.3%
Operating Income
-$5M
-$8M
+33.2%
Net Income
-$4M
-$7M
+48.5%
Revenue Segments
MACI Implants And Kits
$40M
100%
← FY 2024
All Quarters
Q2 2024 →
VCEL Q1 2024 Earnings — Vericel Corporation Revenue & Financial Results | Market Cap Arena